Expertise in
2
conditions

Fadima C. Haidara

Bamako, BKO, ML 
Expertise in
2
conditions
Bamako, BKO, ML 

Overview

Fadima Haidara practices practicing medicine in Bamako, Mali.

Ms. Haidara is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Meningitis, Bacterial Meningitis, Flu, and Diarrhea.

She is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Bamako, BKO, Mali
Other Locations
Mali

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Observer-blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Two Formulations of Investigational Meningococcal Groups ACYWX Conjugate Vaccine, Administered to Healthy Malian Children 12-16 Months of Age
A Phase 2, Observer-blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Two Formulations of Investigational Meningococcal Groups ACYWX Conjugate Vaccine, Administered to Healthy Malian Children 12-16 Months of Age
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Biological
Study Phase: Phase 2
Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age
Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Biological
Study Drugs: NmCV-5, Menactra
Study Phase: Phase 3
View 1 Less Clinical Trial

48 Total Publications

Infant Growth After Mass Administration of Azithromycin: Secondary Outcomes of a Cluster Randomized Clinical Trial.
Infant Growth After Mass Administration of Azithromycin: Secondary Outcomes of a Cluster Randomized Clinical Trial.
Journal: JAMA network open
Published: June 10, 2026

Frequently Asked Questions about Fadima C. Haidara

Is Fadima C. Haidara a top-rated expert for Meningitis?

MediFind is an objective health platform that identifies experts based on real-world data. Fadima C. Haidara is classified as an Advanced expert for Meningitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Fadima C. Haidara participate in research or clinical trials?

Yes. Fadima C. Haidara has published 48 articles and abstracts on conditions like Meningitis. You can view a list of Fadima C. Haidara's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Haidara's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile